0001209191-22-056316.txt : 20221109
0001209191-22-056316.hdr.sgml : 20221109
20221109210307
ACCESSION NUMBER: 0001209191-22-056316
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221107
FILED AS OF DATE: 20221109
DATE AS OF CHANGE: 20221109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gao Hanlin
CENTRAL INDEX KEY: 0001684532
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37894
FILM NUMBER: 221374590
MAIL ADDRESS:
STREET 1: 2325 CLUB VISTA DRIVE
CITY: GLENDORA
STATE: CA
ZIP: 91741
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulgent Genetics, Inc.
CENTRAL INDEX KEY: 0001674930
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 812621304
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205
CITY: TEMPLE CITY
STATE: CA
ZIP: 91780
BUSINESS PHONE: 626-350-0537
MAIL ADDRESS:
STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205
CITY: TEMPLE CITY
STATE: CA
ZIP: 91780
FORMER COMPANY:
FORMER CONFORMED NAME: Fulgent Diagnostics, Inc.
DATE OF NAME CHANGE: 20160517
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-07
0
0001674930
Fulgent Genetics, Inc.
FLGT
0001684532
Gao Hanlin
C/O FULGENT GENETICS, INC.
4978 SANTA ANITA AVE, STE 205
TEMPLE CITY
CA
91780
0
1
0
0
Chief Scientific Officer
Common Stock
2022-11-07
4
A
0
51723
0.00
A
906927
D
Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio.
(continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date.
/s/ Paul Kim as Attorney-in-Fact
2022-11-09